The scientific advisor for Operation Warp Speed floated the idea today of cutting the Moderna doses in half, from two 100 microgram doses to two 50 microgram doses. 1/n nytimes.com/live/2021/01/0…
It appears that he’s relying on Phase 2 trial results, in which 200 people under 55 got 50 micrograms of Moderna and had comparable antibody responses to people who got 100 micrograms. 2/n
That assumes that antibody levels are a correlate of protection. There’s data from monkeys that this *might* be true, but nothing yet from people that I’ve seen. nytimes.com/2020/12/04/hea… 3/n
And there’s the 200 people who got 50 micrograms in the Phase 2 study. After running a 30,000-person Phase 3 trial, that’s a pretty small hook to hang one’s hat on.
Moderna didn’t reply to @KatherineJWu right away, so we’ll see what they say. /end

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Carl Zimmer

Carl Zimmer Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @carlzimmer

31 Dec 20
I've been working with @13pt on a series of brief visual explainers for how different leading vaccines work. Here's a thread of links, starting with Novavax nytimes.com/interactive/20…
How the Pfizer-BioNTech vaccine works nytimes.com/interactive/20…
How the Moderna vaccine works nytimes.com/interactive/20…
Read 10 tweets
12 Oct 20
Vaccines are essential to fighting back the coronavirus. If one gets authorized in the next few months, what will that mean for 2021? One expert put it this way to me: get ready for “complexity and chaos and confusion.” Here’s my preview for @nytimes nytimes.com/2020/10/12/hea… 1/9
The first vaccine may be mediocre. A superior one may still be in development. But the first vaccine’s authorization could immediately affect all the other vaccines still in Phase 3 trials—and could seriously hamper vaccines in earlier stages of research. 2/9
To have enough doses for the whole country by the spring, the US government is counting on several vaccines getting emergency authorization. But guidelines for choosing between them could be very challenging, because their trials are all running separately. 3/9
Read 9 tweets
27 Aug 20
Thread: You may have heard of #COVID-19 vaccines in advanced clinical trials—Moderna, Pfizer, AstraZeneca and the like. But there’s a huge second wave of vaccines on their way. nytimes.com/2020/08/27/hea… [1/7]
I recently decided to take a look at this second wave. I reached out to all the companies and universities I could find that have announced preclinical studies since the beginning of the pandemic. [2/7]
I was able to confirm that 88 vaccines are still being actively investigated at the preclinical stage. Of these, 67 are on track to go into clinical trials in humans between now and the end of 2021. [3/7]
Read 7 tweets
20 Jul 20
Big morning for updates to the @nytimes coronavirus vaccine tracker. In fact, I need a thread! nytimes.com/interactive/20… 1/9 #covid19
First up: Oxford scientists publish their first clinical trial paper on their chimp adenovirus vaccine, to be made by Astra Zeneca. Phase I/II trial indicates it’s safe (lots of mild side effects), produces some antibodies, some interferon. 2/9
CanSinoBio has its own paper out in the Lancet, demonstrating an immune response to a vaccine based on another adenovirus, Ad5 3/9
Read 9 tweets
6 May 20
My Twitter ramblings yesterday have crystallized into a short piece on #covid19 mutations: nytimes.com/2020/05/06/hea…
@edyong209 A few key tips for reporting on mutation preprints...
Read 11 tweets
3 May 20
A lot of us science writers realized at some point a while back that we were going to be full-time #covid19 writers for a while. Maybe a very long while. Still, this past week felt especially bizarre, story-wise. An ICYMI thread 1/8
This week I helped put together this infographic: "How Coronavirus Mutates and Spreads" nytimes.com/interactive/20… (En espanol nytimes.com/es/interactive… ) 2/8
Working with @13pt on these visual explainers been a real privilege. Images can communicate some concepts so much better than words. Here’s a piece we did earlier on the SARS-CoV-2 genome: nytimes.com/interactive/20… and one on how the virus invades: nytimes.com/interactive/20… 3/8
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!